| Original language | English |
|---|---|
| Pages (from-to) | 385-390 |
| Number of pages | 6 |
| Journal | Neurology and Therapy |
| Volume | 7 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - 1 Dec 2018 |
Keywords
- Equivalence
- Follow-on glatiramer acetate
- Glatiramer acetate
- Multiple sclerosis
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Neurology and Therapy, Vol. 7, No. 2, 01.12.2018, p. 385-390.
Research output: Contribution to journal › Letter › peer-review
TY - JOUR
T1 - Letter to the Editor Regarding
T2 - A Comprehensive Review on Copemyl ®
AU - Comi, Giancarlo
AU - Nicoletti, Ferdinando
AU - Canonico, Pier Luigi
AU - Centonze, Diego
N1 - Funding Information: Disclosures. Prof. Giancarlo Comi has received in the past year personal compensation for consulting services and/or speaking activities from Teva, Novartis, Sanofi Genzyme, Merck Serono, Biogen, Roche, Almirall, Cel-gene, Forward Pharma, Medday. Prof. Ferdi-nando Nicoletti has received in the last 3 years consultancy fees from Biogen, Lundbeck, Novartis, Alfa-Sigma, FB-Health, Roche, Otsuka, Janssen, and Teva. Prof. Pier Luigi Canonico has received in the last 3 years honoraria, consultancy fees or paid testimony from AbbVie, Amgen, Amicus Therapeutics, Angelini, Astra Zeneca, Biogen, Biomarin, Boheringer Ingel-heim, Celgene, CSL-Behring, Daiichi Sankyo, Eli Lilly, Incyte Biosciences, Intercept, Jazz Pharmaceuticals, Laboratoire CTRS, Leo Pharma, Lundbeck, Menarini, Merck, MSD, Novo Nordisk, Otsuka, Roche, Sage Therapeutics, Sanofi, Shire, Takeda, Tesaro, Teva, UCB. Prof. Diego Centonze is an Advisory Board member of Almirall, Bayer Schering, Biogen, GW Pharmaceuticals, Merck Serono, Novartis, Roche, Sanofi-Genzyme, Teva and received honoraria for speaking or consultation fees from Almirall, Bayer Schering, Biogen, GW Pharmaceuticals, Merck Serono, Novartis, Roche, Sanofi-Gen-zyme, Teva. He is also the principal investigator in clinical trials for Bayer Schering, Biogen, Merck Serono, Mitsubishi, Novartis, Roche, Sanofi-Genzyme, Teva. His preclinical and clinical research was supported by grants from Bayer Schering, Biogen Idec, Celgene, Merck Serono, Novartis, Roche, Sanofi-Genzyme and Teva.
PY - 2018/12/1
Y1 - 2018/12/1
KW - Equivalence
KW - Follow-on glatiramer acetate
KW - Glatiramer acetate
KW - Multiple sclerosis
UR - https://www.scopus.com/pages/publications/85058970157
U2 - 10.1007/s40120-018-0115-y
DO - 10.1007/s40120-018-0115-y
M3 - Letter
SN - 2193-8253
VL - 7
SP - 385
EP - 390
JO - Neurology and Therapy
JF - Neurology and Therapy
IS - 2
ER -